StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
MKPL.NS$4.98-0.40%
Fair $4.98+0.0%

MKPL.NS

M. K. Proteins Limited

Consumer Defensive / Packaged FoodsNSE

$4.98

-0.02 (-0.40%)

Fairly Valued+0.0%Fair Value $4.98Fund rank 23/100 · Data gapFallback financials|
SA 27/D
F-Score: 1/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 17%

FCF escenarios

weak_data · normalized FCF $-58.8M · quality 39.7/100

Data gap 23/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 6/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

27/100

D

Piotroski

1/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · MKPL.NSLocal privado en este navegador · M. K. Proteins Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$1.9B

P/E

22.6x

↑

EV/EBITDA

17.7x

↑

ROE

12.1%

↑

Gross Margin

6.2%

↓

Debt/Equity

0.56

↑
52-Week Range$5
$4$10

TradingView lightweight chart

MKPL.NS price, volumen y niveles de valoración

Último $4.980Periodo +487.8%
Fair value: $4.980

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+1.5%

FCF CAGR

—

FCF margin

-6.9%

FCF / Net income

-2.19x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $2.68B · net income $84.0M · FCF $-183.5M

2022-FY → 2025-FY

Gross margin

6.2%-1.0% pts

Operating margin

4.6%-1.2% pts

Net margin

3.1%-0.8% pts

FCF margin

-6.9%-2.3% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$2.68B$2.68B$2.46B$3.15B$2.56B
Net Income$84.0M$84.0M$112.1M$109.3M$101.8M
EBITDA$129.1M$129.1M$170.6M$176.5M$157.9M
EPS0.220.220.300.290.27
Gross Margin6.2%6.2%8.8%6.5%7.3%
Operating Margin4.6%4.6%6.7%5.3%5.8%
Net Margin3.1%3.1%4.6%3.5%4.0%
Balance Sheet
Debt/Equity0.560.560.330.910.97
Cash Flow
Free Cash Flow$-183.5M$-183.5M$265.1M$-58.8M$-116.9M
Returns
ROE12.1%12.1%18.4%21.9%26.2%
Valuation
P/E22.6422.6441.3390.907.84
EV/EBITDA17.7217.7228.3358.647.45
P/B2.742.747.5919.842.05
Growth & Yield
Revenue Growth9.0%9.0%-22.0%23.0%—
EPS Growth-26.7%-26.7%3.4%6.9%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

26.2%

muy exigente

EPS terminal req.

$0.44

Spread vs growth

-52.8%

5Y implied EPS CAGR

19.4%

exigente

EPS terminal req.

$0.53

Spread vs growth

-46.1%

10Y implied EPS CAGR

14.6%

razonable

EPS terminal req.

$0.86

Spread vs growth

-41.3%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -30.3%

Total return

-30.3%

Start / end P/E

23.8x → 22.6x

EPS bridge

0.30 → 0.22

Residual

+1.3%

EPS growth-26.7%
Multiple rerating-5.0%
Dividend+0.0%
Residual / FX / buybacks / cross-term+1.3%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.